We are no longer enrolling for the PI activity on insomnia.
Please check back soon for more programs.
Program Description:
Postgraduate Institute for Medicine and Fortis Spectrum have launched a new CME series called TRIAD. This program is targeted toward physicians, nurse practitioners, and physician assistants who are committed to making practice changes in the diagnosis and management of their patients with INSOMNIA. Participants will be guided by experts through a performance improvement (PI) initiative that includes access to two Webcasts and mentoring with these experts that will allow each clinician to make improvements in the care of their insomnia patients. Registration for this free program is on a first come, first served basis.
- Release date: May 2008
- Expiration date: May 2009
- Estimated time to complete activity: 20 hours
- Notice as to the type of hardware and software needed to participate in the activity: Internet browser
- Mechanism for the learner to contact PIM: www.pimed.com
Jointly sponsored by Postgraduate Institute for Medicine and Fortis Spectrum
This activity is supported by an educational grant from Takeda Pharmaceuticals North America, Inc.
Program Features:
Your participation in this activity will be supported by:
- Our TRIAD website, which will include access to the latest literature around insomnia, supplemental educational resources, and forms to input your data
- Support from nationally-known faculty experts via webcast and email
- Ongoing support from the CME office at Postgraduate Institute for Medicine
Target Audience:
Primary care physicians, nurse practitioners, and physician assistants
This activity is designed to assist clinicians in the primary care setting to address these barriers within their own practice setting and implement a strategy to improve patient care and outcomes related to the diagnosis and treatment of insomnia.
Educational objectives:
As a result of these activities, participants will:
- Analyze their own knowledge gaps and other practice barriers regarding the diagnosis and treatment of patients with insomnia
- Develop and implement an Action Plan designed to improve their practice in the diagnosis and treatment of patients with insomnia
- Evaluate the results of their Action Plan
- Assess and reflect on future opportunities for change to further improve patient care outcomes
Faculty:
- David Neubauer, MD, Assistant Professor/Associate Director, Johns Hopkins Sleep Disorders Center, Baltimore, MD
- Gary Richardson, MD, Senior Research Scientist, Sleep Research Laboratory, Senior Staff Physician in Endocrinology, Henry Ford Hospital, Detroit, MI
- Phyllis Zee, MD, Associate Professor, Northwestern University School of Medicine, Evanston, IL
Educational Needs Addressed:
Insomnia remains inadequately identified and treated. Approximately one third of US adults report difficulty sleeping, and 10-15% have the clinical disorder of insomnia.1 For those patients in the primary care setting, approximately half have sleep difficulties, many undetected by health care professionals.2
A recent review illustrated 5 barriers to the recognition, diagnosis, and treatment of insomnia in primary care settings:
- Inadequate knowledge base: majority rate their knowledge of sleep medicine as "fair"
- Office visit time constraints: time may be inadequate for sleep difficulties to be addressed
- Lack of "sleep" discussions: Less than half of patients with insomnia have discussed the problem, with most discussions patient-initiated
- Misperceptions regarding treatment: Health professionals may have greater concerns than warranted about the safety and efficacy of pharmacologic treatments
- Lack of evidence for functional outcomes: Although treatments for insomnia reduce symptoms in the short term, there is inadequate evidence for long-term efficacy, improvements in daytime functioning, or the impact on co morbid disorders.
What will you gain from this?
- Improved patient care, including better diagnosis of patients with insomnia and more effective management of patient under treatment for insomnia
- Increased understanding of ways to improve office "teamwork" in the care of insomnia patients
- Generation of practice improvement data showing significant improvements in proactively discussing sleep, diagnosing and treating insomnia, and improved patient outcomes.
Accreditation Statement:
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and Fortis Spectrum. PIM is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation:
Postgraduate Institute for Medicine designates this educational activity for a maximum of 20 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest:
Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter |
Reported Financial Relationship |
David Neubauer, MD |
Consulting Fees (e.g., advisory boards): Neurocrine; sanofi-aventis; Takeda Pharmaceuticals North America, Inc. |
Gary Richardson, MD |
Consulting fees (e.g., advisory boards): Takeda Pharmaceuticals North America, Inc.; Fees for Non-CME Services Received Directly from a Commercial Interest or their Agents (e.g., speakers' bureaus): sanofi-aventis; Takeda Pharmaceuticals North America, Inc. |
Phyllis Zee, MD |
Royalty: Lippincott and Wilkins |
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Planner or Manager |
Reported Financial Relationship |
PIM Clinical Reviewers: Jan Hixon, RN, BSN, MSN; Trace Hutchison, PharmD; Linda Graham, RN, BSN; and Jan Schultz, RN, BSN, MSN |
Have no real or apparent conflicts of interest to report. |
Jon Kaeuper |
Jon Kaeuper has no real or apparent conflicts of interest to report. |
Amy Louise Novak |
Amy Louise Novak has no real or apparent conflicts of interest to report. |
Method of Participation:
There are no fees for participating and receiving CME credit for this activity. During the period May 2008 through May 2009 participants must 1) submit online forms based on patient chart reviews (Stage A); 2) participate in a didactic lunchtime lecture (Stage B); 3) participate in a second lunchtime didactic program dedicated to case studies and issues identified by learners during the interval (Stage C); 4) complete the evaluation form; and 7) submit the evaluation form online.
A statement of credit will be issued only upon completion of each stage of the program and a certificate will be mailed to you within 4 weeks.
Media:
Online Performance Improvement Program
Disclosure of Unlabeled Use:
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Postgraduate Institute for Medicine (PIM), Fortis Spectrum and Takeda Pharmaceuticals North America, Inc. do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, Fortis Spectrum and Takeda Pharmaceuticals North America, Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer:
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
1. Ohayon MM. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev. 2002;6:97-111.
2. Allaert FA, Urbinelli R. Sociodemographic profile of insomniac patients across national surveys. CNS Drugs. 2004;18 (suppl 1): 3-7.
3. Benca RM. Diagnosis and treatment of chronic insomnia: a review. Psychiatr Ser. 2005;56:332-343.
